Join Equillium for a virtual investor event to share new insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis.

The event will be presented by Stephen Connelly Ph.D., Equillium’s Chief Scientific Officer, and include new preclinical data evaluating several clinically relevant AhR modulators and further characterization of the relationship between AhR activation and miR-124 induction in both immune and epithelial cells.

The webinar will present new data and insights that support a unifying mechanistic framework linking ligand-dependent AhR signaling to miR-124. These findings have important implications for both mechanistic interpretation and the rational development of therapies targeting the AhR/miR-124 axis in inflammatory disease.

A live question and answer session will follow the formal presentations.